Trial Condition(s):

Eye Diseases

Study for collection of Aflibercept data in Routine Practice (CODEX)

Bayer Identifier:

17867

ClinicalTrials.gov Identifier:

NCT02811692

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The French CODEX study is designed as a national database to describe, in routine medical practice, functional and anatomical responses to intravitreal Aflibercept injection, in a large population of anti-VGEF-naïve patients presenting with wet Age-related Macular Degeneration (wAMD), Central Retinal Vein Occlusion (CRVO),Branch Retinal Vein Occlusion(BRVO), or Diabetic Macular Edema (DME). This national database will gather databases from French private and public ophthalmologic centers.

Inclusion Criteria
- Aged ≥18 years old 
 - Anti-VEGF (Vascular Endothelial Growth Factor)  treatment naïve 
 - Intravitreal (IVT) aflibercept injection treatment follows the recommendations made within the EYLEA Summary of Product Characteristics
 - Diagnosed with wAMD (wet Age-related Macular Degeneration), macular edema following CRVO (Central Retinal Vein Occlusion), macular edema following BRVO (Branch Retinal Vein Occlusion), or DME (Diabetic Macular Edema).
Exclusion Criteria
-             Who have any contraindications listed in the EYLEA Summary of Product characteristics 
 - Participating in an investigational program with interventions outside of routine clinical practice.

Trial Summary

Enrollment Goal
425
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, France

Status
Completed
 

Trial Design